ESMO 2016 Conference Review - focus on Melanoma, reviewed by A/Prof Victoria Atkinson

In this review:

Ipilimumab vs placebo: final OS from EORTC 18071
Ipilimumab 3 mg/kg vs 10 mg/kg
Dabrafenib + trametinib in BRAF V600E/K mutant disease: 3-year OS in COMBI-V
Neo-adjuvant ipilimumab + nivolumab: initial data from OpACIN
Pembrolizumab vs chemo: final OS from KEYNOTE 002
Talimogene laherparepvec + ipilimumab vs ipilimumab alone
Atezolizumab + cobimetinib and vemurafenib
Epacadostat + pembrolizumab: updated data from ECHO202/ KEYNOTE 037
PD-L1 expression as a biomarker for nivolumab + ipilimumab and nivolumab alone
Safety of reduced infusion times of nivolumab + ipilimumab and nivolumab alone

Please login below to download this issue (PDF)